Novo Nordisk Demonstrates Shared Value Through Social Responsibility Initiatives in the United States
(3BL Media / theCSRfeed) January 30, 2012 - In its third Blueprint for Change business case, Novo Nordisk analyses how aligning business strategy with the needs of patients, stakeholders and society has contributed to business success and has helped improve quality of care, early diagnosis and diabetes prevention in the United States.
Social responsibility benefits society and business
Conducted in 2011, the Blueprint highlights shared value creation in a series of social responsibility initiatives, including independent health care professional education. In the United States, Novo Nordisk provided $28 million in educational grants in 2010 and 2011, and since 2005 has supported more than 2,000 educational programmes. Almost all educational activities supported by Novo Nordisk are recognised for continuing medical education (CME) or continuing education (CE). In 2010 alone, Novo Nordisk offered CME and CE programs to more than 700,000 health care professionals. According to the Blueprint, pharmacist intervention improves adherence, reduces diabetes-related complications, improves health status, and has the potential to save $34 billion in health-system costs over the next decade.
Another example is the Novo Nordisk Patient Assistance Program (PAP) that provides medications at no charge to people who are uninsured and are at or below 200% of the Federal Poverty Level. In 2010 the, PAP made treatment accessible to more than 65,000 people, more than double the number of people served in 2007. By 2012, the PAP’s direct cost savings to society is expected to rise to $5.5 million.
The case study also demonstrates how putting patient, stakeholder and societal needs at the forefront of business strategy has resulted in a highly engaged workforce and recognition as a great place to work.
Despite effort, Type 2 diabetes is a growing epidemic
Despite the efforts of Novo Nordisk and the diabetes community, the rise of type 2 diabetes grows unchecked. The Blueprint case invites everyone to contribute to resolving this challenge.
Today, approximately 32 million people are living with diabetes in the United States. Fuelled by poor lifestyle choices and escalating obesity rates, the number of Americans diagnosed with diabetes has increased by more than 65% in the past decade. Over the same period, the number of people at risk of developing type 2 diabetes has risen even more sharply. Moreover, it is believed that one-third of Americans with diabetes are not medically diagnosed. Taken together, these trends accelerate the economic stress that diabetes places on society.
Read the case Blueprint for Change: Creating shared value in the United States.
Novo Nordisk in the United States
Today, the United States is Novo Nordisk's largest market. Novo Nordisk in 2010 held 42 % of the total insulin market measured in volume. The US headquarters is located in Princeton, NJ, and the insulin manufacturing facility is located in Clayton, NC. Approximately 4,000 people are employed by Novo Nordisk in the United States.
Read more about Novo Nordisk US here
About the Blueprint for Change Programme
Novo Nordisk's 'Blueprints for Change' Programme articulates and communicates the sustainable value created through Novo Nordisk's Triple Bottom Line business approach. The Programme is used to reach out to and engage with stakeholders to gauge external perspectives and expertise that can inspire and enable innovation and increased beneficial impacts.
Read more about the Blueprint for Change Programme.
Contact
Corporate
Ole Kjerkegaard Nielsen
Corporate Sustainability
+45 30 79 22 20
United states
Lori Moore
Communications & Public Affairs
+1 609-919-7991
About Novo Nordisk
Novo Nordisk is a global healthcare company with nearly 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 32,000 employees in 75 countries, and markets its products in 190 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. Novo Nordisk is listed in the 2010/2011 Dow Jones Sustainability Indices with agold class rating. For more information, visit novonordisk.com/sustainability.
NOVO20606
